title: HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT.
abstract: Chronic infection by hepatitis C virus (HCV) is one of the main risk factors for the development of liver cirrhosis and hepatocellular carcinoma. However, the emergence of hepatocellular carcinoma (HCC) in non-cirrhotic HCV patients, especially after sustained virological response (SVR) is an unusual event. Recently, it has been suggested that HCV genotype 3 may have a particular oncogenic mechanism, but the factors involved in these cases as well as the profile of these patients are still not fully understood. Thus, we present the case of a non-cirrhotic fifty-year-old male with HCV infection, genotype 3a, who developed HCC two years after treatment with pegylated-interferon and ribavirin, with SVR, in Brazil.
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
authors.forename: Angelo Alves de
authors.initials: AA
authors.lastname: Mattos
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
authors.forename: Patrícia dos Santos
authors.initials: Pdos S
authors.lastname: Marcon
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
authors.forename: Fernanda Schild Branco de
authors.initials: FS
authors.lastname: Araújo
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
authors.forename: Gabriela Perdomo
authors.initials: GP
authors.lastname: Coral
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
authors.forename: Cristiane Valle
authors.initials: CV
authors.lastname: Tovo
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a